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Sphingosine kinase (SK) 1 catalyzes the formation of the bioactive lipid sphingosine
1-phosphate, and has been implicated in several biological processes in mammalian cells, 
including enhanced proliferation, inhibition of apoptosis, and oncogenesis. Human SK (hSK) 
1 possesses high instrinsic catalytic activity which can be further increased by a diverse 
array of cellular agonists. We have shown previously that this activation occurs as a direct 
consequence of extracellular signal–regulated kinase 1/2–mediated phosphorylation at 
Ser225, which not only increases catalytic activity, but is also necessary for agonist-induced 
translocation of hSK1 to the plasma membrane. In this study, we report that the oncogenic 
effects of overexpressed hSK1 are blocked by mutation of the phosphorylation site despite 
the phosphorylation-deficient form of the enzyme retaining full instrinsic catalytic activity. 
This indicates that oncogenic signaling by hSK1 relies on a phosphorylation-dependent 
function beyond increasing enzyme activity. We demonstrate, through constitutive 
localization of the phosphorylation-deficient form of hSK1 to the plasma membrane, that 
hSK1 translocation is the key effect of phosphorylation in oncogenic signaling by this 
enzyme. Thus, phosphorylation of hSK1 is essential for oncogenic signaling, and is brought 
about through phosphorylation-induced translocation of hSK1 to the plasma membrane, 
rather than from enhanced catalytic activity of this enzyme.
 
Sphingosine kinases (SKs) catalyze the formation
of sphingosine 1-phosphate (S1P), a bioactive
lipid that regulates a diverse range of cellular
processes, including cell growth, survival, dif-
ferentiation, motility, and cytoskeletal organi-
zation (1, 2). Some of these cellular processes
are mediated by five S1P-specific G protein–
coupled receptors, whereas other effects appear
controlled by intracellular S1P, through as yet
unidentified intracellular targets (2, 3).
Two human SK isoforms exist (SK1 and
SK2), which differ in their tissue distribution,
developmental expression, catalytic properties,
and somewhat in their substrate specificity (4, 5).
Although these two enzymes appear to have dif-
fering roles (6), several studies have shown the
effects of SK1 in enhancing cell proliferation
and supressing apoptosis (7–9). Furthermore,
we have shown that overexpression of human
SK (hSK) 1 in NIH3T3 fibroblasts results in
acquisition of the transformed phenotype and
the ability to form tumors in mice, demon-
strating the oncogenic potential of this enzyme
(8). Recent work has also demonstrated the
involvement of hSK1 in estrogen-dependent
regulation of breast tumor cell growth and sur-
vival (10, 11), whereas other studies have
shown elevated hSK1 mRNA in a variety of
human solid tumors and inhibition of tumor
growth in vivo by SK inhibitors (12). Thus,
the involvement of hSK1 in cell growth, sur-
vival, and tumorigenesis is well established.
Less clear, however, are the mechanisms
whereby hSK1 brings about these effects. Re-
cent studies have indicated it is independent of
G protein–coupled receptors (13), being medi-
ated solely by intracellular S1P generated by
SK activity. Although the direct targets of in-
tracellular S1P are unknown, hSK1 has been
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implicated in several proproliferative and prosurvival path-
ways, such as activation of extracellular signal–regulated
kinase (ERK) 1/2 (14), phosphatidylinositol-3-kinase (15),
NF-
 
 
 
B (16), and inhibition of caspase activation (9).
We have shown recently that activation of hSK1 occurs, at
least in response to TNF
 
 
 
 and phorbol esters, as a direct con-
sequence of phosphorylation at Ser225 by ERK1/2 (17). The
effects of this single phosphorylation are unusual since it not
only directly increases the catalytic activity of hSK1 but is also
necessary for agonist-induced translocation of this protein
from the cytosol to the plasma membrane. Notably, hSK1 is
phosphorylated to a moderate extent when overexpressed in
cells even in the absence of external stimuli. In the current
study, we report that the ability of overexpressed hSK1 to
support enhanced proliferation, survival, and transformation is
blocked by mutation of the phosphorylation site. This indi-
cates that it is the phosphorylated form of hSK1 that is respon-
sible for these biological effects. Furthermore, we have shown
through constitutive localization of hSK1 to the plasma mem-
brane that these biological effects are brought about through
the phosphorylation-dependent translocation of hSK1 to the
plasma membrane rather than from the observed phosphoryla-
tion-induced increases in hSK1 catalytic activity.
 
RESULTS AND DISCUSSION
Phosphorylation of hSK1 is required for enhanced 
cell proliferation and survival
 
Overexpression of wild-type hSK1 is known to significantly
enhance cell proliferation and survival (7–11, 13), although
the precise molecular mechanisms whereby this occurs are
unknown. These effects are dependent on the catalytic activ-
ity of hSK1 being blocked by the SK inhibitor,
 
 
 
N
 
,
 
N
 
-dimeth-
ylsphingosine (7–9), and appear independent of G protein–
coupled S1P receptors (7, 13). Thus, the enhanced growth
and survival appear due to the action of S1P on as yet un-
identified intracellular targets. To date, it has been considered
that an increase in total S1P levels in the cell, as a conse-
quence of the high intrinsic catalytic activity of the overex-
pressed hSK1 (4), was sufficient to induce these biological
effects (7–11). However, we have noted that even without
external stimulation, overexpressed hSK1 is phosphorylated
to a moderate extent (Fig. 1 and reference 17). Therefore,
we tested whether this phosphorylation was important for
the biological consequences of hSK1 overexpression.
To test whether phosphorylation of hSK1 is important in
proliferation and survival, we examined the ability of the
nonphosphorylatable hSK1
 
S225A
 
 mutant to promote these
Figure 1. Phosphorylation and plasma membrane localization of 
hSK1 enhances cell proliferation and survival. Growth of NIH3T3 cells 
stably transfected with plasmids encoding for wild-type hSK1 ( ), 
hSK1S225A ( ), mp-hSK1 ( ), and mp-hSK1S225A ( ) or the empty vector 
( ) over 5 d in (A) serum-free medium (containing 0.1% BSA), (B) medium 
containing 1% FCS, or (C) 5% FCS. (D) SK activity in these cells after serum 
deprivation for 16 h. Protein expression and phosphorylation status of the 
various hSK1 constructs was determined by Western blot via anti-FLAG 
and anti–phospho-hSK1 antibodies, respectively. (E) Cell proliferation of 
these cells as measured by BrdU incorporation into nacent DNA. (F) Serum 
deprivation–induced apoptosis of these cells as measured by nuclear con-
densation and fragmentation. Data are mean (  SD) from three indepen-
dent experiments (*P   0.05 compared with vector control). 
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processes. Consistent with our previous findings (8), overex-
pression of wild-type hSK1 not only markedly enhanced the
growth of NIH3T3 cells in media containing either 1 or 5%
serum but also conferred to these cells the ability to survive
and grow in the absence of serum (Fig. 1, A–C). In contrast,
however, cells overexpressing hSK1
 
S225A
 
 displayed no such
enhanced growth or serum independence (Fig. 1, A–C).
Notably both wild type and hSK1
 
S225A
 
 were expressed at
similar level, and extracts of the cells possessed comparable
overall SK activities (Fig. 1 D).
Previous studies have shown that the increased growth
rates from overexpression of wild-type hSK1 result from a
combination of both increased cellular proliferation and re-
duced apoptosis (7, 9, 13). Consistent with these studies, as-
says for cellular proliferation by bromodeoxyuridine (BrdU)
incorporation into nascent DNA showed overexpression of
wild-type hSK1 had a significant effect in increasing cell
proliferation (Fig. 1 E). In contrast, however, cells overex-
pressing hSK1
 
S225A
 
 displayed no such enhanced proliferation,
showing comparable incorporation of BrdU as control cells
(Fig. 1 E). Similarly, overexpression of wild-type hSK1 dra-
matically reduced serum deprivation–induced apoptosis, as
measured by condensation and fragmentation of nuclei (Fig.
1 F). Again, however, overexpression of hSK1
 
S225A
 
 showed
markedly different results, providing cells with no such pro-
tection against apoptosis (Fig. 1 F). Therefore, in stark con-
trast to wild-type hSK1 overexpression of the nonphos-
phorylatable hSK1
 
S225A
 
 mutant neither increases proliferation,
nor protects against apoptosis despite both transfected pro-
teins generating similar cellular SK activities. Thus, phos-
phorylation of hSK1 imparts a qualitative change in the en-
zyme that is critical for the signaling processes leading to
enhanced proliferation and survival.
It has been well established that hSK1 translocates from
the cytosol to the plasma membrane upon exposure of cells to
certain agonists (17, 18–21). Although the molecular mecha-
nism whereby translocation of hSK1 occurs is unknown, we
have shown recently that it is dependent on phosphorylation
of hSK1 at Ser225 (17). Therefore, it was important to test
whether translocation was the phosphorylation-dependent
process required for hSK1 signaling. We predicted that if this
was true, then artificially directing hSK1
 
S225A
 
 to the plasma
membrane would restore its ability to promote proliferation
and transformation. Plasma membrane–localized hSK1 pro-
teins were created through addition of the 10–amino acid
Lck tyrosine kinase myristoylation/palmitylation motif to the
N terminus of wild-type hSK1 and hSK1
 
S225A
 
, generating
mp-hSK1 and mp-hSK1
 
S225A
 
, respectively. Overexpression of
these proteins in NIH3T3 cells produced slightly lower cellu-
lar SK activities than that observed with overexpression of
hSK1 and hSK1
 
S225A
 
 (Fig. 1 D). Consistent with previous
studies that have shown this motif is sufficient to target pro-
teins to the plasma membrane (22), we observed a substantial
localization of mp-hSK1 and mp-hSK1
 
S225A
 
 to the membrane
fraction (Fig. 2 A). Further immunofluorescence analysis
(Fig. 2 B) showed clear localization of mp-hSK1 and mp-
hSK1
 
S225A
 
 to the plasma membrane, whereas hSK1 and
hSK1
 
S225A
 
 were mainly present in the cytoplasm. Interest-
ingly, localization of wild-type hSK1 to the plasma
membrane in this manner substantially reduced its basal
phosphorylation (Fig. 1 D). This is presumably due to partial
sequestration of hSK1 away from cytosolic ERK1/2, its up-
stream activating protein kinases (17).
Strikingly, and in stark contrast to hSK1
 
S225A
 
, overex-
pression of mp-hSK1
 
S225A
 
 in NIH3T3 cells conferred an en-
hancement of growth and survival in serum-deprived condi-
tions (Fig. 1, A–C). As expected, mp-hSK1 also had these
effects (Fig. 1, A–C). Further examination of these cells
showed that, like wild-type hSK1, both mp-hSK1 and mp-
hSK1
 
S225A
 
 increased cell growth through enhancing cellular
proliferation and reducing serum deprivation–induced apop-
tosis (Fig. 1, E and F). Similar results were also observed
in HEK293 cells (not depicted). Therefore, localization of
hSK1 to the plasma membrane is sufficient to enhance cellu-
lar proliferation and protect against apoptosis irrespective of
the phosphorylation status of the enzyme. This strongly sug-
gests that phosphorylation of hSK1 mediates these observed
biological effects through inducing translocation of hSK1 to
the plasma membrane rather than as a result of the associated
increase in catalytic activity.
 
Phosphorylation-induced plasma membrane localization 
of hSK1 mediates oncogenic signaling
 
Since we had established that Ser225 phosphorylation of
hSK1 was essential for its effects in enhancing cell prolifera-
Figure 2. Localization of hSK1 to the plasma membrane by the Lck 
tyrosine kinase N-terminal myristoylation/palmitylation motif. (A) Ly-
sates from NIH3T3 cells transfected with wild-type hSK1, hSK1S225A, mp-hSK1, 
and mp-hSK1S225A were fractionated into cytosol (C) and membranes (M) 
and probed via Western blot with anti-FLAG. Data are representative of 
three independent experiments. (B) Fluorescence microscopy of the same 
transfected NIH3T3 cells. Images are representative of  50% of cells ob-
served in three independent experiments. 
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tion and survival, we further investigated its effects on cell
transformation. As described previously (8), wild-type hSK1
exhibited considerable transforming activity when overex-
pressed in NIH3T3 cells, as assayed by colony formation in
soft agar (Fig. 3). In contrast, however, overexpression of
similar levels and catalytic activity of hSK1
 
S225A
 
 resulted in
remarkably less transformation of these cells (Fig. 3). Nota-
bly, these cells expressing hSK1
 
S225A
 
 had considerably higher
SK activity than what we have previously shown necessary
for transformation of NIH3T3 cells by wild-type hSK1 (8).
Therefore, like the situation for enhanced proliferation and
survival, these experiments demonstrate that it is not simply
elevated levels of SK activity that are responsible for cell
transformation but instead indicate that another aspect of the
phosphorylated, activated state of the protein is responsible
for these effects. We have demonstrated previously that
transformation of NIH3T3 cells by oncogenic H-Ras (V12-
Ras) is partially blocked by a catalytically inactive, dominant-
negative form of hSK1, indicating that hSK1 is critically in-
volved in Ras-induced cell transformation (8). Strikingly,
here we find that the nonphosphorylatable hSK1
 
S225A
 
 also
reduced Ras-induced cell transformation, further confirming
the requirement of hSK1 activation in this pathway (Fig. 3).
Therefore, in this context hSK1
 
S225A
 
 is apparently acting as a
dominant-negative form of the protein, despite possessing
full catalytic activity.
Since plasma membrane localisation of hSK1 mediated
the enhanced proliferation and survival resulting from hSK1
overexpression, we next examined its effects on cell transfor-
mation. Like wild-type hSK1, the overexpression of both
mp-hSK1 and mp-hSK1
 
S225A
 
 in NIH3T3 cells resulted in
the formation of vigorous colonies in soft agar (Fig. 3). Al-
though some background colonies where observed in empty
vector control cells, mp-hSK1 and mp-hSK1
 
S225A
 
–overex-
pressing cells produced 20–30-fold greater colonies which
were considerably larger in size. Indeed, the colonies gener-
ated by mp-hSK1 and mp-hSK1
 
S225A
 
 overexpression were
also larger and more numerous than those observed in cells
overexpressing wild-type hSK1 (Fig. 3). Thus, like the situa-
tion for enhanced proliferation and survival, localization of
hSK1 to the plasma membrane is sufficient to enhance cell
transformation irrespective of the phosphorylation status of
the enzyme.
To examine the oncogenic effects of hSK1 phosphoryla-
tion and translocation in animals, NIH3T3 cells stably
expressing the various forms of hSK1 were subcutaneously
injected into NOD/SCID mice. Unlike wild-type hSK1-
transfected cells, which we have previously reported gener-
ate tumors in these mice (8), no tumors formed in six mice
injected with cells expressing hSK1
 
S225A
 
. In contrast, and
consistent with the in vitro experiments, tumors were ob-
served in mice injected with cells expressing mp-hSK1 (five
out of six) and mp-hSK1
 
S225A
 
 (four out of six).
 
Phosphorylation and plasma membrane localization of hSK1 
enhances S1P generation
 
Sphingosine, the substrate of hSK1, is concentrated in the
plasma membrane (23). Therefore, one possible mechanism
Figure 3. Phosphorylation and plasma membrane localization of 
hSK1 leads to transformation. (A) NIH3T3 cells stably transfected with 
empty vector, or plasmids encoding for wild-type hSK1, hSK1S225A, 
mp-hSK1, or mp-hSK1S225A either alone or cotransfected with plasmid 
encoding for an activated mutant H-Ras (V12-Ras) were cultured on soft 
agar. Colonies formed after 3 wk were visualized by MTT staining as de-
scribed previously (8). (B) Quantitation of colony formation in soft agar for 
NIH3T3 cells overexpressing hSK1 proteins alone (gray bars) or in combi-
nation with V12-Ras (black bars). Data are mean (  SD) from three inde-
pendent experiments. 
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for the observed dramatic biological effects of hSK1 localiza-
tion to the plasma membrane is in enhancing S1P generation
by directing hSK1 to its substrate. Therefore, we measured
the effect of plasma membrane translocation of hSK1 on lev-
els of its product, S1P. Overexpression of both mp-hSK1
and mp-hSK1
 
S225A
 
 resulted in similar increases in intracellu-
lar S1P and enhanced S1P release into the media. These in-
creases were substantially greater than that observed with ei-
ther wild-type hSK1 or hSK1
 
S225A
 
 (Fig. 4). These findings
are consistent with our previous reports that Ser225 phos-
phorylation of hSK1 results in increased cellular S1P and
enhanced S1P release from cells (17). This, again, suggests
that phosphorylation-induced translocation of hSK1 to the
plasma membrane is critical for enhanced S1P generation
and the observed subsequent biological effects.
 
Conclusions and implications of this study
 
The involvement of hSK1 in tumorigenesis is becoming in-
creasingly evident, with several studies suggesting that ele-
vated hSK1 levels may be important in this process (8–12).
In this study, however, we have shown that rather than total
hSK1 levels, phosphorylation and subsequent translocation
of hSK1 to the plasma membrane are the critical factors in-
volved in the oncogenic effects of this protein. We have
proposed previously that the substantial basal activity of
hSK1 may reflect an essential housekeeping role that is dis-
tinct from its signaling role (4, 14, 17). Agonist-dependent
translocation may accomplish the differentiation of these two
roles of hSK1. Thus, our studies indicate that disregulation
of hSK1 phosphorylation and localization may be key ele-
ments in the acquisition of malignant phenotypes through
provoking the enhancement of proliferation and, perhaps
most importantly, protection from the apoptotic mecha-
nisms that normally target mutated cells for destruction. This
suggests that targeting the mechanisms driving hSK1 phos-
phorylation and/or translocation may provide precise ave-
nues for future anticancer therapies.
 
MATERIALS AND METHODS
 
Cell culture, transfection, and cell fractionation.
 
Human embryonic
kidney (HEK293T) cells and NIH3T3 fibroblasts were cultured and har-
vested as described previously (14). Stable and transient transfections were
performed using the calcium phosphate precipitation method for HEK293T
cells and Lipofectamine 2000 (Invitrogen) for NIH3T3 cells. Stable trans-
fectants were selected for G418 resistance and pooled to avoid the pheno-
typic artifacts that may arise from the selection and propagation of indi-
vidual clones from single transfected cells. For subcellular fractionation,
postnuclear supernatants of cell lysates were separated into cytosol and
membrane fractions as described previously (17).
 
Antibodies.
 
The M2 anti-FLAG antibody was from Sigma-Aldrich, anti–
H-Ras polyclonal antibody was from Santa Cruz Biotechnology, and
HRP-conjugated anti–mouse and anti–rabbit IgG were from Pierce Chem-
ical Co. Anti-hSK1 and anti–phospho-hSK1 antibodies have been described
previously (17).
 
SK assays and S1P levels.
 
SK activity was determined as previously de-
scribed (14). S1P levels were determined following metabolic labeling of
cells with [
 
32
 
P]orthophosphate as outlined previously (17).
 
Generation of plasma membrane–localized hSK1 constructs.
 
A
plasma membrane–targeted hSK1 construct (mp-hSK1) containing the
myristoylation/palmitylation motif of the Lck tyrosine kinase (MGCGC-
SSHPE) (22) was generated by PCR with oligonucleotide primers 5
 
 
 
-
TAGAATTCGCCACCATGGGCTGTGGCTGCAGCTCACACCCG-
GAAGATCCAGCGGGCGGCC-3
 
 
 
 and SP6 using pcDNA3-hSK1 (4) as
template DNA. The resultant product was then cloned into pcDNA3 (Invit-
rogen) by digestion with EcoRI. The orientation was determined by restric-
tion analysis, and sequencing verified the integrity of the FLAG-tagged
mp-hSK1 cDNA sequence. To generate FLAG-tagged mp-hSK1
 
S225A
 
, the
KpnI–PmlI fragment representing the wild-type 5
 
 
 
 end of pcDNA3-hSK1
 
S225A
 
(17) was replaced with the 150-bp KpnI–PmlI pcDNA3-mp-hSK1 DNA
fragment that contains the Lck myristoylation/palmitylation motif.
 
Immunofluorescence.
 
Cells were plated onto fibronectin-coated 8-well
glass chamber slides at 10
 
4
 
 cells/well and incubated for 24 h. The cells were
fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized with
0.1% Triton X-100 in PBS, and incubated with M2 anti-FLAG antibody in
PBS containing 3% BSA and 0.1% Triton X-100 for 1 h. The immuno-
complexes were then detected with FITC-conjugated anti–mouse IgG.
Fluorescence microscopy was performed on an Olympus BX-51 micro-
scope equipped with a fluorescein excitation filter (494 nm) acquired to a
Cool Snap FX charge-coupled device camera (Photometrics).
 
Cell growth, bromodeoxyuridine incorporation, staining of apop-
totic nuclei, and tumorigenesis assays.
 
Assays for cell growth were
performed by incubating cells in 48-well plates (2,500 cells per well) in me-
dium containing 5 or 1% FCS, or serum free medium (containing 0.1%
BSA) as described previously (8). Cell numbers were determined at the indi-
cated times using the MTS assay (Promega). BrdU incorporation into na-
scent DNA were used as a measure of cell proliferation. Cells were plated
onto 8-well glass chamber slides (Nalge Nunc) coated with fibronectin at 10
 
4
 
cells/well and grown for 24 h in DMEM with 2% FCS. Cells were then in-
cubated with 10 
 
 
 
M BrdU for 3 h, and then fixed and stained for its incor-
Figure 4. Phosphorylation and plasma membrane localization of 
hSK1 lead to increased intracellular and extracellular S1P levels. 
Intracellular and extracellular S1P levels were determined in NIH3T3 cells 
stably transfected with empty vector, or plasmids encoding for wild-type 
hSK1, hSK1S225A, mp-hSK1, and mp-hSK1S225A. Data are mean (  SD) from 
three independent experiments. 
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poration using an anti–BrdU-FLUOS antibody (Roche) following the man-
ufacturer’s protocol. Cells positive for BrdU incorporation were visualized
with an Olympus BX-51 fluorescence microscope with at least 300 cells
scored per point. Apoptosis was assessed by staining cells with 1 
 
 
 
g/ml DAPI
in methanol for 15 min at room temperature. Apoptotic cells were identified
by condensation and fragmentation of nuclei using fluorescence microscopy
and expressed as a percentage of the total cells counted. A minimum of 300
cells were scored per point. Colony formation in soft agar and tumorigenesis
assays in mice were performed as detailed previously (8) with approval from
the Institute of Medical and Veterinary Science Animal Ethics Committee.
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